Voriconazole is available as a lyophilized powder in single-use (preservative-free) vials containing 200 mg of voriconazole with 3.2 g of sulfobutyl ether ß-cyclodextrin sodium3233; 3348 or hydroxypropyl ß-cyclodextrin3347 and bearing a vacuum.3233; 3347; 3348 Vial contents should be reconstituted with 19 mL of sterile water for injection, and the vial should be shaken until all of the powder is dissolved to yield 20 mL of a voriconazole 10-mg/mL solution.3233; 3347; 3348 A 20-mL standard (non-automated) syringe should be used for reconstitution to ensure that the exact amount of sterile water for injection is added; the vial should be discarded if the vacuum does not draw the diluent into the vial.3233; 3347; 3348
The reconstituted solution is a concentrate that must be diluted in a compatible solution to a concentration of 0.5 to 5 mg/mL prior to intravenous administration.3233; 3347; 3348 In order to achieve a final concentration in this range, the manufacturer recommends that a volume be removed from the infusion bag or bottle that is at least equivalent to the volume of drug to be added prior to addition of the drug.3233; 3347; 3348
Trade Name(s)
Vfend I.V.
Voriconazole is administered by intravenous infusion in a compatible infusion solution at a concentration between 0.5 and 5 mg/mL over 1 to 2 hours at a maximum rate of 3 mg/kg/hr.3233; 3347; 3348 Voriconazole should not be administered as an intravenous bolus injection.3233; 3347; 3348
Voriconazole is available as a lyophilized white to off-white cake or powder.3233; 3347; 3348 Intact vials should be stored at controlled room temperature.3233; 3347; 3348 Voriconazole powder reconstituted as directed is chemically and physically stable for 24 hours at 2 to 8°C; however, because no antimicrobial preservative is present, the manufacturer recommends that the drug be used immediately after reconstitution.3233; 3347; 3348 Voriconazole solutions should be visually inspected for particulate matter and discoloration prior to administration.3233; 3347; 3348 Vials of voriconazole are intended for single use, and any remaining drug should be discarded.3233; 3347; 3348
Y-Site Injection Compatibility (1:1 Mixture)
Additional Compatibility Information
Other Drugs
Manufacturers state that voriconazole must not be infused concomitantly with any short-term infusion of concentrated electrolytes, even if the infusions are running in separate intravenous lines or cannulas. Voriconazole may be infused at the same time as other intravenous solutions containing nonconcentrated electrolytes, but still must be infused through a separate line.3233; 3347; 3348
Parenteral Nutrition Solutions
Manufacturers state that voriconazole may be infused at the same time as parenteral nutrition solutions, but must be infused through a separate line. If a multiple-lumen catheter is used, the parenteral nutrition solution must be administered through a different port than the one used for voriconazole administration.3233; 3347; 3348
For a list of references cited in the text of this monograph, search the monograph titled References.